Hutchison China MediTech and AstraZeneca will present data from the ongoing phase II clinical trial of savolitinib in patients with papillary renal cell carcinoma at the 2017 Genitourinary Cancers Symposium.
The symposium, which is sponsored by the American Society of Clinical Oncology, is being held in Orlando, Florida, from 16-18 February.
Savolitinib, a highly selective inhibitor of c-Met receptor tyrosine kinase, has shown early clinical benefit in multiple Phase I and II studies in a number of cancers.
It was developed as a potent and highly selective oral inhibitor specifically designed to address issues observed in the clinic with first-generation c-Met inhibitors, including renal toxicity.
Story provided by StockMarketWire.com